Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Twister Biotech is raising $3,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christopher Coker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Twister Biotech

Twister Biotech was created around the break-through and disruptive platform technology, MiniVectors, that originated in the laboratory of Dr. Lynn Zechiedrich at Baylor College of Medicine. MiniVectors are supercoiled DNA minicircles containing ONLY the sequence of interest, as small as a few hundred base pairs, compared to traditional plasmids that are orders of magnitude larger. Experiments have demonstrated that MiniVectors are a safe and effective platform for getting DNA into ôdifficult-to-transfectö cells, such as primary and stem cells. Twister’s primary mission is to provide MiniVectors to researchers to enable better transfection efficiencies and allow longer-term effects to be observed.

To learn more about Twister Biotech, visit http://twisterbiotech.com/

Contact:
Christopher Coker, Chief Executive Officer
832-236-1326
https://www.linkedin.com/in/chris-coker-20b33923/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved